ID   SF-TY
AC   CVCL_3163
DR   BioSample; SAMN03471063
DR   JCRB; JCRB0075
DR   JCRB; NIHS0016
DR   Wikidata; Q54952881
RX   PubMed=8320183;
CC   Doubling time: ~40 hours (Note=Lot 102198), ~1.5 days (Note=Lots 07092007 and 08082018), ~42 hours (Note=Lot 07162010), 34-54 hours (Note=Lot 10192015), ~52 hours (Note=Lot 03272017), ~41 hours (Note=Lot 12202021) (JCRB=JCRB0075).
CC   HLA typing: A*02,24; B*05,w22 (JCRB=JCRB0075).
CC   Discontinued: JCRB; NIHS0016; true.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
ST   Source(s): JCRB=JCRB0075
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D5S818: 11
ST   D7S820: 11
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Finite cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 12
//
RX   PubMed=8320183; DOI=10.1007/BF02633962;
RA   Ichinose, Ichiro
RA   Nakano, Shuji
RA   Esaki, Taito
RA   Koga, Tatsuhiko
RA   Mitsugi, Kenji
RA   Yamada, Hidenori
RA   Niho, Yoshiyuki
RT   "Growth modulation of human tumor cells by a growth-inhibiting
RT   activity derived from tumorigenic V79 Chinese hamster cells.";
RL   In Vitro Cell. Dev. Biol. Anim. 29:332-338(1993).
//